As one of the leading companies in the immune cell therapy with Regulatory T (Treg) cells, TeraImmune is providing innovative Treg cell therapies for the patients with autoimmune diseases. Our proprietary technologies make it possible to consistently produce disease-specific Tregs that retain their suppressive function. TeraImmune is building a solid foundation for Treg cell therapy and aims to conduct a first-in-human study with a ‘FVIII-TCR Treg’ targeting the anti-FVIII antibody formation in severe Hemophilia A.
Hemophilia A is in the IND-enabling stage and is expected to get the IND clearance in June-August, 2022.
Hemophilia A is in the IND-enabling stage and is expected to get the IND clearance in June-August, 2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Hemophilia A, Multiple Sclerosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
